AGEN:NSD-Agenus Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 2.66

Change

-0.03 (-1.12)%

Market Cap

USD 0.55B

Volume

2.94M

Average Target Price

USD 8.00 (+200.75%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate to treat tumor; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that is in Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial for dose escalation study; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody to deplete regulatory T cells, which is in a Phase 1 clinical trial; AGEN-1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, an anti-TIGIT monospecific antibody. In addition, it develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4, as well as AGENT 797, an iNKT cells that is in Phase 1 clinical trial for the treatment of COVID-19-related pneumonia; and in preclinical stage to treat multiple myeloma/B cell malignancies and solid tumors. The company has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-15 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-0.16 (-0.10%)

USD64.10B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

+3.97 (+1.83%)

USD56.20B 21.10 15.27
REGN Regeneron Pharmaceuticals, Inc

+13.48 (+2.80%)

USD51.55B 15.77 12.24
ALXN Alexion Pharmaceuticals, Inc

+2.25 (+1.45%)

USD34.14B 57.09 33.71
BNTX BioNTech SE

+8.12 (+6.12%)

USD31.31B -99,999.99 N/A
BGNE BeiGene, Ltd

+7.16 (+2.38%)

USD27.77B N/A N/A
SGEN Seagen Inc

+5.44 (+3.77%)

USD26.14B 42.79 34.88
RPRX Royalty Pharma plc

-0.47 (-1.12%)

USD25.57B 22.60 15.33
GMAB Genmab A/S

+0.31 (+0.89%)

USD22.68B 26.59 3.21
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing AGEN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -16.35% 28% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.35% 28% F 13% F
Trailing 12 Months  
Capital Gain 1.92% 35% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.92% 35% F 13% F
Trailing 5 Years  
Capital Gain -38.00% 40% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.00% 40% F 14% F
Average Annual (5 Year Horizon)  
Capital Gain 0.43% 35% F 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.43% 34% F 28% F
Risk Return Profile  
Volatility (Standard Deviation) 35.70% 80% B- 47% F
Risk Adjusted Return 1.19% 35% F 28% F
Market Capitalization 0.55B 60% D- 53% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -3.96 28% F 65% D
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 58.70% 97% A+ 98% A+
Return on Assets -39.21% 25% F 8% F
Debt to Equity Ratio -9.27% 90% A- 93% A
Technical Ratios  
Short Ratio 6.07 30% F 14% F
Short Percent 14.59% 15% F 13% F
Beta 1.37 50% F 36% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector